Fig. 7: CHFR promotes apoptosis and correlates with good clinical outcome in malignant breast cancer.

a LM2 cells were treated with or without DOX and TSA as indicated and immunoblotted with the FASN, Cleaved Caspase-3, and HSP90 antibodies. b, c SUM159 cells were treated as described in a and stained with propidium iodide and Annexin V-FITC and then analyzed by flow cytometry (b); c showed the percentage of early apoptotic (Annexin V+PI−; c) cells in SUM159 cells. d Tumor growth curves of nude mice with subcutaneous injection of LM2 cells. From day 7, mice received every 3 days intraperitoneal injections of doxorubicin with or without TSA. n = 3 mice per group. e Kaplan–Meier curves showing the distant relapse-free survival of patients with high or low expression of CHFR in the mesenchymal/basal subtype breast tumors. f Kaplan–Meier curves showing the distant relapse-free survival of patients with high or low expression of CHFR in the basal-like 1 subtype breast tumors. Significance of Mock versus DOX or TSA is shown. n = 3 wells per group. Data in c, d are the mean of biological replicates from a representative experiment, and error bars indicate s.e.m. Statistical significance was determined by a two-tailed, unpaired Student’s t test. The experiments were repeated three times. Statistical significance in e, f was determined by log-rank test.